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Combination of whole cell pertussis vaccine and the pneu-
mococcal surface protein A (PspA) antigen: proposal of
a combined vaccine against pertussis and pneumococcal
diseases
M.L. Sarno de Oliveira, D.M. Ferreira, A.T. Moreno, P.C.D.
Ferreira, E. Miyaji, P. Ho ∗
Instituto Butantan, Sao Paulo, Brazil
Background: Streptococcus pneumoniae (pneumococcus)
is one of the major agents of respiratory acute diseases,
accounting for 1 million deaths per year around the world.
In developing countries, pneumococcal diseases kill 800,000
children annually. PspA is a surface pneumococcal antigen,
shown to elicit protection against animal models of pneu-
mococcal infections, in different vaccine formulations. The
whole cell pertussis vaccine (WCP) is widely used in devel-
oping countries and its ﬁrst dose is indicated to be given
at 2 months of age. As an inactivated bacteria-based vac-
cine, it has the potential to exert adjuvant activity upon
co-administration with other antigens.
Methods: Here, we analyzed the adjuvant activity of WCP
in combination with PspA and tested the efﬁcacy of WCP-
PspA nasal vaccination against a pneumococcal challenge in
mice.
Results: Nasal immunization of Balb/C mice with WCP-
PspA elicited higher amounts of anti- PspA IgG and sIgA than
the immunization with PspA alone. Mice immunized with
the combination were 100% protected after a respiratory
lethal challenge, whereas immunization with PspA alone
produced around 60% protection. In time course experiments
of challenged mice, IL-6, TNF and IFN-g cytokine signal-
ing was observed in vaccinated animals, with a peak 12 h
after challenge followed by a quick reduction in secretion,
indicating controlled inﬂammatory responses. In contrast,
cytokine secretion in control mice remained high long after
challenge, showing that these animals are unable to con-
trol the inﬂammatory response elicited by pneumococcal
infection. Pneumococci loads increase in the lungs of con-
trol animals and reach the bloodstream 30 h after infection,
leading to death at 72 h after infection. On the other hand,
vaccinated mice displayed steadily pneumococcal numbers
in the lungs in the ﬁrst hours and a marked decrease 72 h
after challenge. In this group, pneumococci did not reach
the bloodstream. Sera collected from WCP-PspA immunized
mice displayed increased capacity of induction of comple-
ment deposition on bacteria surface, indicating a potential
role of antibodies in the protection observed. Moreover, sera
from WCP-PspA immunized mice protected naïve mice in
passive immunization experiments.
Conclusion: These results open the possibility for the
combination of WCP vaccines with PspA, taking advantage of
the adjuvant activity of WCP. Supported by: FAPESP, CNPq,
Fundac¸ão Butantan.
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Background: Streptococcus pneumoniae (pneumococ-
us) is responsible for the majority of pneumonia cases
round the world. Despite the effectiveness of conju-
ate vaccines, the costs of the available formulations are
rohibitive for mass vaccination in developing countries.
rotein antigens are alternatives for the constitution of
ow costs-formulations that can elicit immunity to differ-
nt pneumococcal serotypes. PspC is a virulence factor that
lays a role in the adhesion of the pathogen to epithelial
ells and evasion from the immune system. Intact bacteria
isplay adjuvant activities when administered in association
ith antigens, through the binding of their components to
eceptors present on immune cells surface.
Methods: In this work, mucosal vaccines composed of
spC and two different bacteria as carriers and/or adju-
ants were tested in mice. The ﬁrst strategy consisted in
actobacillus casei expressing PspC (L. casei-PspC), as a live
accine. The second consisted in the combination of recom-
inant PspC with the whole cell pertussis vaccine (WCPV).
Results: Nasal immunization of mice with L. casei-PspC
id not stimulate the production of systemic and mucosal
nti-PspC antibodies. Despite the absence of speciﬁc anti-
odies, this vaccine inhibited pneumococcal nasopharyngeal
olonization of immunized mice, when compared with mice
noculated with saline or L. casei. In this same model, sub-
ingual immunization with L. casei-PspC did not produce
signiﬁcant effect on pneumococcal colonization. On the
ther hand, nasal immunization with PspC-WCPV induced
igh levels of anti-PspC antibodies. Mice immunized with
spC-WCPV presented a signiﬁcant inhibition of pneumococ-
al colonization, when compared with mice inoculated with
aline or WCPV. The reduction in pneumococcal colonization
as much more accentuated for the PspC-WCPV formula-
ion than for L. casei-PspC. Analysis of cytokine secretion
y spleen cells from mice 5 days after the colonization chal-
enge showed two different patterns. Mice immunized with
. casei-PspC displayed a dramatic reduction in IFN-g and
NF-a secretion whereas mice immunized with PspC-WCPV
isplayed increased IFN-g and IL-17 secretion.
Conclusion: Our results indicate that two different mech-
nisms are likely to be involved in the protection elicited
y both vaccines. The mechanisms elicited by PspC-WCPV
eem to be more effective in the control of pneumococcal
asopharyngeal carriage. Financial support: FAPESP, CNPq,
undac¸ão Butantan.
oi:10.1016/j.ijid.2010.02.608
